FN1 and melanoma: An example of such resistance-driving ECM interaction is the increased resistance to BRAF inhibitors in melanoma, which occurs when CAFs generate a fibronectin-rich stiff TME that leads to enhanced cancer cell survival via the fibronectin-activated β1-integrin-FAK-ERK axis [158].